| Literature DB >> 20674859 |
Pieter Goossens1, Marion J J Gijbels, Alma Zernecke, Wouter Eijgelaar, Monique N Vergouwe, Ingeborg van der Made, Joris Vanderlocht, Linda Beckers, Wim A Buurman, Mat J A P Daemen, Ulrich Kalinke, Christian Weber, Esther Lutgens, Menno P J de Winther.
Abstract
Inflammatory cytokines are well-recognized mediators of atherosclerosis. Depending on the pathological context, type I interferons (IFNs; IFNalpha and IFNbeta) exert either pro- or anti-inflammatory immune functions, but their exact role in atherogenesis has not been clarified. Here, we demonstrate that IFNbeta enhances macrophage-endothelial cell adhesion and promotes leukocyte attraction to atherosclerosis-prone sites in mice in a chemokine-dependent manner. Moreover, IFNbeta treatment accelerates lesion formation in two different mouse models of atherosclerosis and increases macrophage accumulation in the plaques. Concomitantly, absence of endogenous type I IFN signaling in myeloid cells inhibits lesion development, protects against lesional accumulation of macrophages, and prevents necrotic core formation. Finally, we show that type I IFN signaling is upregulated in ruptured human atherosclerotic plaques. Hereby, we identify type I IFNs as proatherosclerotic cytokines that may serve as additional targets for prevention or treatment. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20674859 DOI: 10.1016/j.cmet.2010.06.008
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287